The AHA today commented on the Food and Drug Administration’s draft guidance for industry and FDA staff on clinical decision support software as part of the agency’s efforts to implement Section 3060(a) of the 21st Century Cures Act. AHA expressed concern that “FDA’s interpretation of certain criteria could result in many existing CDS algorithms being subject to the FDA approval process and ultimately slow the pace of innovation and development of new algorithms to support better patient care and outcomes.” In its letter, AHA shared specific recommendations with FDA and said it “looks forward to working with the FDA to ensure the agency’s regulatory approach to implementing Section 3060(a) is consistent with the language and intent of the Cures Act and prioritizes patient safety while at the same time allowing hospitals and health systems to continue to implement innovative decision support tools.”

Headline
The AHA will host a webinar Dec. 2 at 1 p.m. ET that will explore strategies on protecting patient care, identifying critical systems that must remain…
Headline
An FBI report released Nov. 13 details actions by cyber actors weaponizing ARTEX, an open-source, large language model-driven agentic artificial intelligence…
Headline
The AHA will host a webinar Dec. 1 at 1 p.m. ET on how to create and build an effective artificial intelligence training program. Attendees will learn how to…
Headline
A Gallup survey published Nov. 9 on patient comfort with artificial intelligence in care found that 56% of U.S. adults who visited a primary care provider in…
Headline
Christine Moutier, M.D., chief medical officer at the American Foundation for Suicide Prevention, discusses the usage of artificial intelligence chatbots among…
Headline
Christine Moutier, M.D., chief medical officer at the American Foundation for Suicide Prevention, discusses the usage of artificial intelligence chatbots among…